Project Details
Description
APPRAISE 2: A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects With a Recent Acute Coronary Syndrome
| Status | Finished |
|---|---|
| Effective start/end date | 6/1/09 → 7/21/11 |
Funding
- BRISTOL-MYERS SQUIBB PHARM RES
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.